Stifel Initiates Coverage On Immunic with Buy Rating, Announces Price Target of $2.5

Benzinga Newsdesk www.benzinga.com Neutral 62.6%

Neg 0% Neu 62.6% Pos 0%

Stifel analyst Paul Matteis initiates coverage on Immunic (NASDAQ:IMUX) with a Buy rating and announces Price Target of $2.5.